To determine the cellular effects and potential toxicity of exogenously administered recombinant human epidermal growth factor 1-48 (EGF 1-48 ) in primates, intravenous bolus injections were given to 2 cynomolgus monkeys per sex at 0 (vehicle control). 10, 100, 500 (females only), and 1,000 &mu;g/kg/day (males only) for up to 2 wk. Males given the suprapharmacologic dose of 1,000 &mu;g/kg did not tolerate treatment and were necropsied after 5 days of dosing. All other monkeys completed the 2-wk study. Necropsy findings included enlarged, discolored, pale tan livers at 500 &mu;g/kg and greater, firm, thickened pancreata in 500-&mu;g/kg females, and enlarged salivary glands at all doses. Relative liver weights were increased at 500 and 1,000 &mu;g/kg; mean salivary gland weights in all dose groups were greater than in controls. Histopathologic changes were primarily those of diffuse epithelial cell hypertrophy and hyperplasia in liver (hepatocytes and biliary tract), pancreas, salivary glands, tongue, esophagus, stomach, small and large intestine, and gallbladder. Alterations were dose-related in intensity and occurred in at least some tissues at the lowest dose. In gastric glands, colon crypts, pancreatic ducts, biliary tract, and salivary glands, differentiated epithelial cells were replaced by cells of less differentiated phenotype. These morphologic alterations were consistent with exuberant proliferation induced by this epithelial mitogen. The extent of the proliferative response in tissues of the digestive tract attests to the potency of this fragment of human EGF 1-53 in primates. Furthermore, the epithelial proliferation was significantly greater than that reported previously in EGF-treated rodents.
INTRODUCTION
Epidermal growth factor (EGF), a mitogen for epithelial cells in many organs, plays an important role in regulation of tissue growth and repair (10) . To date, the assessment of biologic effects of exogenous EGF in vivo has been performed largely in rodents and rabbits using EGF from mouse, rat, and humans and from several sources, such as salivary gland, urine, or recombinant products. EGF-induced trophic and cell proliferation effects in the gastrointestinal tract of rodents have been described (2, 19, 22, 26, (47) (48) (49) . Significant differences in these proliferative effects were found depending on the route of administration (54) . When the growth factor was given intravenously (16, 21) or subcutaneously (44) , there were more marked effects than either intragastric or intracolonic routes. In addition to stimulatory effects on stomach and intestine, EGF-related mitogenic effects have been described for pancreas (13) and liver (31, 51) .
EGF's potential role as a therapeutic agent for gastrointestinal injury has also been explored. EGF prevented cysteamine-induced ulcers in rats (27) and minimized intestinal injury in experimental colitis (29, 39) . These and other studies corroborate the proliferative and potential therapeutic effects of EGF on the gastrointestinal tract, although effects on specific segments were briefly mentioned, not fully described, or inconsistent under various experimental conditions (11, 20, 32, 36, 55) .
Although EGFs from different animal species have close amino acid sequence homology, species-related sequence differences exist and such differences could modulate host or tissue responses (12, 23, 34, 40, 50) . To minimize the impact of phylogenetic factors on the magnitude and nature of tissue responses, recombinant human products such as recombinant human EGF (rhEGF) may be more appropriately studied in primates. To date, only a few studies have examined the effects of exogenously administered rhEGF in nonhuman primates (41, 52) .
These studies involved rhesus monkeys treated in utero during late gestation and focused on EGF-related effects on the respiratory system and colon. Histologic effects in adult cynomolgus monkeys induced by human EGF isolated from urine have also been reported (30) . To our knowledge, systematic histopathologic changes due to rhEGF on tissues of the primate digestive system have not been described.
Recombinant human EGF,-,, (rhEGF,_4g), a bioactive fragment of the 53-amino acid human gene product, consists of 48 amino acid residues of the parent moiety and lacks 5 consecutive amino acids from the C-terminus. This 48-amino acid fragment retains mitogenic and biologic activity similar to the complete polypeptide (24) . Truncation of the EGF polypeptide below 48 amino acids significantly lowers mitogenic activity in in vitro assays (33) . Recombinant human EGFI-41 used in our studies was produced by E. coli transfected with the human EGF gene. Exploring the preclinical safety in cynomolgus monkeys, suprapharmacologic doses were administered to determine the magnitude and distribution of mitogenic activity and the potential toxicity. Indicative of the mitogenic activity of this compound, nearly all epithelia of the body had pronounced systemic hyperplastic changes (43) . This report describes the morphologic changes in the digestive system of rhEGF,_4g-treated cynomolgus monkeys after daily intravenous administration for up 2 wk.
MATERIALS AND METHODS
Recombinant human EGF,-4, was purified from transfected E. coli cultures in the Biotechnology Department, Parke-Davis Pharmaceutical Research Division. Following detailed biophysical characterization, the purified product used in this study had an active moeity of 87.6% and was reconstituted in phosphate buffer (20 mM, pH 6.0) containing 0.01 % Tween 80. Dilutions of this stock solution with sterile saline containing 0.5 mg/ml monkey albumin (rhesus monkey Fraction V) were made fresh before use. Dosing volume administered was I ml/kg at a rate of 0.5 ml/min. Adult wild-caught cynomolgus monkeys (Macaca fascicularis) were obtained from Hazleton Research Products, Inc., and conditioned in environmentally controlled animal quarters. Animals were housed individually in stainless-steel cages and fed dry Purina Certified Primate Chow 5048 supplemented with fresh fruit. Fresh water was supplied ad libitum. The study was conducted according to established guidelines for animal welfare.
Two monkeys per sex per group were administered vehicle (controls) or rhEGFI-4, at 10 and 100 >g/kg/day for up to 2 wk by bolus injection into saphenous veins. Similarly, 2 females and 2 males were given 500 and 1,000 ~,g/kglday, respectively. Animals were evaluated daily for clinical signs, and physical examinations were performed pretest and weekly during the study. Blood pressure was monitored predose and 30 min after dosing on day 1 and before termination. At the end of the study, animals were euthanatized and necropsied. Organ weights and ratios were determined for major organs. Because of the small number of animals per treatment group, the individual data are presented. Representative samples of major tissues and organs were fixed in 10% buffered formalin and processed for light microscopy. Tissue sections were stained with hematoxylin and eosin.
RESULTS

Clinical Findings
Hypoactivity, lacrimation, dehydration, and nasal discharge were seen in monkeys at 500 and 1,000 [ig/kg. Weak pulse and hypothermia were noted before death in the 1000 ~Lg/kg males after 5 days of treatment. One 1,000-fJLg/kg male was prostrate and died, and the other animal was sacrificed moribund. Monkeys given doses of 500 pLg/kg or less survived to study completion. Soft feces and diarrhea were seen in monkeys at 100 and 500 ,g/kg, primarily during week 2. Emesis occurred sporadically throughout the 14 days of study at 10-500 ~,g/kg, but frequency was not dose-related. Monkeys at all doses had transient pallor and hypotension 30 min postdose (38) . In addition, sporadic transient postdose salivation and episodes of dose-related reduced food consumption were observed.
Gross Pathology
Hepatomegaly was noted in a monkey at 100 pLg/kg and in all monkeys at 500 and 1,000 jig/kg; pale tan discoloration of the liver occurred at 500 and 1,000 pLg/ kg. The liver-to-brain weight ratio was 2-fold greater than controls in the l,000-)JLg/kg moribund male and 1.5-fold greater in the 500-tJLg/kg females (Table 1 ). Parotid and mandibular salivary glands were enlarged in 1 or more monkeys at all doses. Mean mandibular salivary glandto-brain weight ratios in treated monkeys were 1.25-1.5fold greater than controls at all doses. The pancreas of both 500-jjLg/kg females was firm and thickened and had accentuated lobulation. Stomach-to-brain weight ratios of females at all doses were increased from 1.2to 1.8-fold in a manner that was dose-related.
Microscopic Findings
The incidence and relative intensity of epithelial hyperplasia in digestive tract tissues are summarized in Table II. Hyperplastic alterations were dose-related and noted in some tissues of monkeys at the lowest dose (10 pLg/ kg) administered. Such proliferative alterations were not observed in control monkeys of this or previous studies in our laboratory. The most responsive tissue of the digestive system was the stomach, evidenced by the significant degree of detectable changes at lower doses (10 and 100 pLg/kg).
Tongue and Esophagus (Figs. [1] [2] [3] [4] . Monkeys at 100-1,000 u-g/kg had uniformly thickened stratified squamous epithelia of tongue and esophagus due to increased cell layers and cell hypertrophy. At 500 and 1,000 ~,g/kg, the epithelial thickness reached approximately twice that of the controls. Rete pegs of the stratified squamous epithelium were elongated and widened. Germinal zones of the epithelia had hypertrophic epithelial cells with enlarged nuclei and nucleoli and increased mitoses. Skeletal muscle fiber necrosis was seen in the esophageal tunica muscularis of both 1,000 pLg/kg males. values indicated in the table: g = absolute organ weight; g/% = ratio of organ to body weight X 100; g/g = ratio of organ to brain weight X 100. Units are grams, except body weight, in kilograms.
Animal sacrificed moribund after 5 days of treatment.
Stomach (Figs. 5-8). Dose-related proliferative alterations occurred in gastric pits and glands of the cardiac, pyloric, and fundic regions of the stomach. The gastric mucosa was thickened overall at 100, 500, and 1,000 pLg/kg due to the hyperplastic changes in the glands and pits. Gastric mucosal changes were exemplified by those that occurred in the fundus. At 10 ~,g/kg, there were significantly increased undifferentiated cells in the neck region and upper portion of fundic glands. Mitotic cells were common in the upper mucosa and were seen deeper in the glands than in controls but were largely found in the upper one-third of the gland. At 100 ~,glkg, the epi-thelia of the upper half of fundic glands consisted largely of undifferentiated epithelial cells with only few interspersed differentiated parietal cells. Mitoses were common throughout the upper half of the glands. Cellular changes in the lower portions of fundic glands were less pronounced. At 500 [Lg/kg, undifferentiated cells and mitoses were present throughout the gland. Only few differentiated parietal cells were evident and displayed pale, rarefied cytoplasm. Fundic glands of monkeys given 1,000 pLg/kg for 5 days were lined entirely by undifferentiated hypertrophic epithelial cells. Differentiated parietal or chief cells were not evident or rare. Gastric pits were significantly elongated at 100-1,000 ~,gikg; at 500 and 1,000 pLg/kg, mucus cells lining pits and surface epithelia were small and had reduced apical mucin globules.
Small Intestine ( Figs. 9 and 10 ). Monkeys at 500 and 1,000 Rg/kg had villus enterocyte hypertrophy, increased epithelial cell density on the villus surface, and pseudostratification of epithelial cell nuclei. The closely packed arrangement of cells caused undulations of the epithelial surface, particularly in high-dose males and females. Nuclei of epithelial cells were large and vesicular. Distinctive alterations of crypts and crypt cells were not apparent.
Large Intestine (Figs. 11 and 12) . Crypts of treated monkeys had hyperplastic epithelium at 100 pLg/kg and greater. Cells in the crypts were basophilic and had large vesicular nuclei with prominent nucleoli. Goblet cells were reduced in number with small apical globules at 500 and 1,000 Rg/kg. Mitotic cells were numerous, and crypt depth was increased. Sparse neutrophilic infiltrates were observed in colonic or cecal crypts at 1,000 Rg/kg. Pancreas (Figs. 13 and 14) . Monkeys at 10 and 100 pLg/kg had variably sized foci of hypertrophic and hyperplastic acinar cells interspersed within normal parenchyma. At 500 and 1,000 [Lg/kg, hypertrophic and hyperplastic alterations were diffuse, involving all segments of ducts and lobules. In high-dose males and females, lobules were enlarged and borders were less defined. Papilliform projections of hypertrophic and less differentiated epithelial duct cells were present in lumina of larger intralobular and interlobular ducts. Centroacinar cells and intercalated duct epithelial cells were also uniformly hy-TABLE II.-Incidence and relative intensity of epithelial hyperplasia in EGF,_4g-treated cynomolgus monkeys.&dquo; a Designations in parentheses indicate intensity or range of intensity scores as follows: + = minimal: -~' -4-= mild; ++T = moderate; ++++ = marked. Hyperplastic epithelial alterations were not seen in tissues of vehicle controls. b Animals sacrificed moribund or found dead after 5 days of treatment: n = 2 per group.
Flos. 1, 2.-Tongue epithelium of a control (1) and EGF,_48 500 ~,g/kg-treated (2) monkey. The epithelium in the treated monkey is thickened due to increased number of cell layers and cell hypertrophy. The rete pegs are elongated. H&E.
X93.
pertrophic and mitotic centroacinar and duct epithelial cells were common. Acinar cells had substantially reduced secretory granules in 1 100-jjLg/kg monkey and in all monkeys given higher doses. Cross-sections of ducts appeared disproportionately increased throughout the pancreatic parenchyma and were conspicuous at the lobule periphery. Primitive, newly formed ductlike structures composed of epithelial cells surrounding a central lumen FIGS. 3, 4.-Esophageal mucosa from control (3) and 500 ~.g/kg-treated (4) monkey. Epithelium thickness is increased 2-fold due to increased number of cell layers and cell hypertrophy. H&E.
FiGs. 5-8.-Fundic stomach from a control (5) and 1,000 pLg/kg-treated (6) monkey. Mucosa of treated monkeys is thicker than controls. and parietal and chief cells of the treated monkey are largely replaced by undifferentiated cells. H&E.
X93. Higher magnification of the base of fundic glands of control (7) and 1,000 fJ.-glkg-treated (8) monkey. Mitoses in glands are increased in number and extend to the base of fundic glands. H&E.
X370.
FIGS. 13, 14. -Pancreas from a control (13) and 1,000 pLg/kg-treated (14) monkey. In the treated animal, the epithelial cells formed papilliform projections into the interlobular duct lumina. Centroacinar and duct cells are hypertrophic and more prevalent than in controls. Mitoses are common.
H&E.
x 185.
were present at the periphery of some lobules and in the perilobular interstitium. These ducts were not associated with defined pancreatic acinar units. Slight interstitial fibrosis was seen in some regions concomitantly with pronounced epithelial proliferation in monkeys at 500 and 1,000 ~,g/kg. Conspicuous structural changes were not apparent in pancreatic islets, and mitoses were not observed in islet cells.
Liver (Figs. I S-17 ). Proliferative hepatic changes occurred in both hepatocytes and biliary epithelia at 100 pLg/kg and greater. Hepatocellular hypertrophy with anisokaryosis, increased cytoplasmic eosinophilia, and mitoses were evident at 500 and 1,000 pLg/kg and most prominent in the periportal region. The epithelium of bile ducts and small ductules was hypertrophic and hyperplastic in all dose groups except the low dose. Increased numbers of bile ductule profiles were present in the portal regions, and immature newly formed bile ductules were present in the periportal parenchyma in apposition with hypertrophic hepatocytes. Epithelia of large ducts showed nuclear pseudostratification, and at 500 or 1000 pLg/kg the epithelia formed papilliform projections within ducts. Mitoses were common at all levels of the biliary tree at 500 and 1,000 pLg/kg. Scanty small foci of coagulative hepatic necrosis were noted in 1 monkey each at 100, 500, or 1,000 pLg/kg. Gallbladder (Figs. 18 and 19) . Epithelial cells at 100 pLg/kg or higher doses were hypertrophic and hyperplas-FIGS. 9, 10.-Small intestinal villi from control (9) and 1,000 pLg/kg-treated (10) monkey. The cell density of hypertrophic enterocytes along the basement membrane appears increased in treated monkeys, together with enhanced stratification of nuclei. H&E.
Fms. 11, 12.-Large intestinal crypts of a control monkey (11) and a 1.000 pLg/kg-treated animal (12) . The epithelial cells of the large intestinal crypts in the treated monkey are hypertrophic and less differentiated than in controls. The goblet cells are decreased in size and number, whereas mitoses are increased. H&E.
x 185. tic. Nuclear pseudostratification as seen in the gut and ducts of pancreas and biliary system occurred at 100 pLg/kg and above. The number of mitoses was increased. At 500 and 1,000 ~,g/kg, arborous branching of epithelia was evident with extensive crowding of epithelial cells. Prominent undulation of the epithelial surface was evident.
Salivary Glands (Figs. 20 and 21 ). Proliferative changes in salivary glands occurred in monkeys at all doses and were most conspicuous in interlobular and large intralobular ducts. At 500 and 1,000 pLg/kg, the duct epithelia formed short papilliform fronds in the lumina of interlobular ducts. The bilayered arrangement of epithelia of smaller interlobular ducts was less ordered in treated monkeys with enhanced multilayering. Cells of striated and intercalated ducts were hypertrophic, and the basal polarity of nuclei was reduced or lost. An apparent increase in duct profiles occurred within lobules. Mitotic cells were frequent throughout the duct epithelia. Acinar cells were depleted of secretory granules and had enlarged vesicular nuclei. At 10 and 100 ~,g/kg, a doserelated increase in cellularity occurred in the basal layer of the smaller bilayered interlobular ducts, and the number of cell layers increased in larger interlobular ducts.
DISCUSSION
The findings from this study indicate that a 48-amino acid recombinant fragment (rhEGFI-48) of the 53-amino acid human EGF induces rapid and pronounced doserelated epithelial proliferation with concomitant structural alterations in the digestive tract of nonhuman primates. These characteristic proliferative changes are the result of potent mitogenic properties of this growth factor. The proliferation appeared organized and regular, and in no instance were there anaplastic changes. Though this report documents effects in the digestive tract, pronounced EGF-related proliferative changes were observed systemically (43) . The significant responses in the digestive tract of nonhuman primates parallel the observations that EGF modulates epithelial proliferation in humans with necrotizing enteritis (53) .
Findings from this and other studies in our laboratory indicate that nonhuman primates are exquisitely sensitive to the mitogenic effects of rhEGF,-,,. Whether rhEGF-41 was administered by daily intravenous bolus injections or continuous intravenous infusion, hyperplastic and hypertrophic responses in cynomolgus monkeys tissues were far more robust than in adult rats given comparable or larger doses (42, 43, 51 ) . Prolonged treatment of rats for lower doses (5, 42) . The reduced responsiveness of the rat digestive system relative to that of primates was unexpected but was corroborated by findings of Maraschin et al (30) . These investigators administered human-derived urogastrone-EGF (uEGF) composed of a mixture of 1-50, 1-51, and 1-52 amino acid fragments of human EGF to rats and cynomolgus monkeys intravenously at doses from 0.3 to 3 mg/kg/day for up to 4 wk. Urogastrone-EGF at these doses was not tolerated by monkeys, resulting in mortality or early sacrifice before study termination. Rats, however, tolerated these doses for the study duration with no apparent detrimental affects on general health. Furthermore, in spite of the longer treatment of rats, structural changes were not reported for glandular stomach or intestine, whereas hyperplastic changes occurred throughout the digestive tract of monkeys (30) .
Reasons for species differences in sensitivity to human EGF including rhEGF,-,, are not known but certain postulates deserve consideration. EGF derived from different species and sources are not homologous (6, 7, 12, 17, 37, 46, 50) . They differ in amino acid sequence, polypeptide length, and consequentially 3-dimensional conformation. Differences in ligand affinity, growth factor internalization, systemic clearance, or cardiovascular factors may also moderate the host response (34) . Intuitively, differences in species sensitivity to human EGF could be phylogenetically based and thus explain the relative activity to this recombinant human gene product in rats and monkeys.
The segmental proliferation of cells in the digestive tract resulted in increased cell populations with differentiated phenotype in the liver (hepatocytes) and organs with stratified squamous epithelium; less differentiated cells made up a significant proportion of the epithelial FIGs. 18. 19.-Gallbladder mucosa from control (18) and 1.000 pLg/kg-treated (19) monkey. In the treated animal, the epithelial cell density Î5 increased in the mucosa, and cell nuclei show significant stratification. Notice the enhanced undulation of the epithelial surface. H&E.
X93.
FIGS. 20, 21.-Mandibular salivary gland of control (20) and 500 pLg/ kg-treated (21) monkey. The epithelial cell layer forms papilliform or multilayered projections into the lumen of the interlobular duct. Acinar cells are hypertrophic and depleted of secretory granules. H&E. X 185. population in the stomach, large intestine, pancreas, and biliary tract. The retention of cells with less differentiated phenotype would likely affect physiologic processes in tissues that require highly specialized cells in precise anatomic locations to carry out specific functions. The gastric mucosa of rhEGF¡_4s-treated monkeys best exemplified a tissue with a substantial population of undifferentiated cells. It is uncertain what effects the widespread presence of undifferentiated cells had on the intricacies of gastric physiology. Several studies indicate that EGF (including rhEGF1_-+8) alters, directly or indirectly, a variety of gastric functions. EGF administration reduces gastric acid secretion (4, 10, 14, 24, 33) . In the present study, the protracted changes of fundic glands in monkeys could lead to reduced gastric acid secretion due to the persistent reduction in differentiated parietal cells. EGF administration also affects serum gastrin levels under certain circumstances (8, 15) . Levels of serum gastrin from rhEGF 1-48-treated monkeys at 500 pLg/kg were increased approximately 4.5-6.6-fold greater than baseline (unpublished observations). Increases in serum gastrin levels may be a direct effect of EGF stimulation of gastric antral G cells (18) , indirectly through increased luminal pH, or by interruption of a feedback response due to reduction of differentiated parietal cells. Other gastric functions potentially and selectively affected by longer term administration of EGF include pepsin and intrinsic factor output (28) .
Persistence of a large proportion of cells with a less differentiated phenotype in other portions of the gastrointestinal tract also presumably impacted physiologic functions and homeostasis. Increasing episodes of soft feces or diarrhea in treated animals suggest disturbances in secretory or absorptive functions of the intestine or exocrine pancreas. Studies in rodents and rabbits have shown that EGF can affect exocrine pancreatic function (25, 35) . The substantiative reduction in phenotypically differentiated cells from gastric glands, pancreas, and biliary system likely caused alterations in digestive processes that may have reduced absorption of nutrients and solutes. Further studies in monkeys should address specific alterations caused by protracted retention of less differentiated epithelial cells in the gastrointestinal tract.
Several changes in gastrointestinal tissues were considered adverse effects not directly attributed to the expected biologic activity of this growth factor. Necrosis of skeletal muscle fibers in the esophageal tunica muscularis occurred in high-dose males only. Focal or multifocal hepatocellular necrosis were seen sporadically in animals at 100 ug/kg and greater, with no direct relationship to dose. The mechanisms of these effects are not known. Fibroplasia in areas of pancreatic epithelial hyperplasia was also not predicted from the mitogenic properties of the growth factor. Fibroplasia of the pancreas has been reported in transgenic mice overexpressing transforming growth factor alpha (TGFa) (3, 45) . TGFa and EGF bind to the same EGF receptor in epithelial and some mesenchymal cells (1) . Interstitial fibrosis could be a direct response of ligand interaction with mesenchymal cell receptors or secondary to epithelial changes occurring in the pancreas.
Monkeys administered 1,000 pLg/kg did not tolerate prolonged treatment for reasons that are likely multifactorial and complex. The dose-related structural changes in gastrointestinal tissues likely contributed in a variety of ways to the clinical deterioration of animals. Other rhEGF,_4g-related effects in extragastrointestinal tissues also likely contributed to the clinical deterioration of these animals. For instance, pronounced and dose-related systemic hypotension and pallor occurred in monkeys after dosing, presumably as a result of direct vasodilatory effects of EGF (38) . Hypotension occurred without compensatory increases in heart rate. Such changes presum-ably resulted in substantially reduced systemic perfusion. In addition, pronounced structural effects occurred in numerous extragastrointestinal tissues (43) , and some of these also likely caused adverse effects. For example, profound structural changes in the kidneys (data not presented) included persistence of less differentiated and multilatyered epithelium in renal tubules and collecting ducts. These changes may have directly impaired renal functions including electrolyte, urea, and solute processing. Azotemia and some electrolyte disturbances occurred in both animals at this dose. Structural changes in the thyroid and adrenal glands indicated that disturbed endocrine homeostasis was also a consequence of treatment at high doses. Certainly the substantial widespread alterations in many epithelia likely had some impact on the animals' well-being. The exaggerated proliferative and adverse biologic effects observed in the high-dose monkeys provoke scientific interest. However, the suprapharmacologic doses administered to these monkeys and the duration of treatment far exceed any expected treatment paradigm for potential human application.
In summary, intravenously administered rhEGF,-41 induced significant proliferative epithelial changes in all segments of the digestive system in cynomolgus monkeys. These proliferative effects on the mucosa of nonhuman primates are observed with EGFs of different amino acid sequence, from 1-48 through 1-53, including a 1-50/1-51/1-52 fragment mixture. It appears that these moieties stimulate the epithelium, but the extent of the differences in proliferative potential between fragments of different length in the amino acid chain is not established. The structural changes seen with rhEGFI-41 were consistent with the biologic activity of a potent epithelial mitogen.
